@article{3f13b3120a5e40e9bc7536b5c16b4d88,
title = "Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling",
abstract = "Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provides effective low-intensity treatment options. Rational therapy selection strategies that consider individual's risk of therapy-related toxicities and probability of disease control can maximize benefits of available treatments. Studies have demonstrated that fitness level, measured by geriatric assessment can predict therapy-related toxicities, whereas cytogenetic and mutation results correlate with the probability of responses to standard chemotherapy. We are approaching an era when we move from “one size fits all” approach to personalized therapy selection based on geriatric assessment, genetic and molecular profiling.",
keywords = "Acute myeloid leukemia, Genetic profiling, Geriatric assessment, Molecular mutation, Older adults, Therapy selection",
author = "Bhatt, {Vijaya Raj}",
note = "Funding Information: This work was supported by the National Institute of General Medical Sciences, 1 U54 GM115458, which funds the Great Plains Institutional Development Award (IDeA) Clinical Translational Research (CTR) Network, and the Fred and Pamela Buffett Cancer Center Support Grant from the National Cancer Institute (P30 CA036727). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. None. Funding Information: VRB reports receiving consulting fees from Pfizer, CSL Behring, Agios, Incyte, Partner Therapeutics and Abbvie, and research funding from Incyte, Tolero Pharmaceuticals, Inc, and National Marrow Donor Program. Funding Information: This work was supported by the National Institute of General Medical Sciences , 1 U54 GM115458 , which funds the Great Plains Institutional Development Award (IDeA) Clinical Translational Research ( CTR ) Network, and the Fred and Pamela Buffett Cancer Center Support Grant from the National Cancer Institute ( P30 CA036727 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",
year = "2019",
month = may,
doi = "10.1016/j.ctrv.2019.04.001",
language = "English (US)",
volume = "75",
pages = "52--61",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
}